Research project This project explores the feasibility, preliminary efficacy and safety of an open-label application of MDMA in participants 18–25 years old with treatment resistant depression with the long term aim to conduct a fully powered multi-center randomized controlled trial.
Most young patients with depression do not benefit long term from available treatments. There is a great need for new effective treatment options. A novel methodology is 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT). MDMA-AT has been shown to be a potent catalyst to the therapeutic process and enhancer of the therapeutic alliance. Memories of stressful life events related to the onset of depression may be effectively and rapidly reconsolidated in MDMA-AT and promote long-term relief of depressive symptoms.
